Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2858 + Anlotinib in Recurrent/Metastatic Endometrial Cancer
NCT05121363Phase 2Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Dec 2021
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label trial of bemosesuglimab in endometrial carcinoma, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Objective Response Rate at 2 years. Status: unknown.
02
Drugs
bemosesuglimab
03
Conditions
endometrial carcinoma
Beyond the preview
Go deeper on NCT05121363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05121363.